Want to see FR:AB full AI Analyst Report?
AB Science SA (AB) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Masitinib 4.5 Mg/Kg/Day, Riluzole (100 Mg) | Amyotrophic Lateral Sclerosis (Als) | Phase III | Not Yet Recruiting | Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients | Sep 11, 2025 | ― |
| Standard of Care, Masitinib (4.5) | Alzheimer Disease | Phase III | Not Yet Recruiting | Masitinib in Patients With Mild Alzheimer's Disease | Sep 29, 2022 | ― |
| Best Supportive Care, Masitinib 4.5 Mg/Kg/Day, Masitinib 6.0 Mg/Kg/Day | Mast Cell Activation Syndrome | Phase II | Unknown | Masitinib for the Treatment of Severe Mast Cell Activation Syndrome | Jul 02, 2022 | ― |
| Masitinib (4.5) | Progressive Multiple Sclerosis | Phase III | Recruiting | Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis | Jun 28, 2022 | ― |
| Azacitidine, Ab8939 | Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, In Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia | phase1AndPhase2 | Recruiting | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Jan 12, 2022 | ― |
| 14C-Ab1010 | Healthy Volunteers | earlyPhase1 | Completed | Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects | Dec 27, 2021 | ― |
| Masitinib Mesylate | COVID19, Sars-Cov2 Infection, Coronavirus Disease 2019 | Phase II | Unknown | Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 | Sep 16, 2021 | ― |
| Best Supportive Care, Masitinib, Isoquercetin | Sars-Cov 2, Coronavirus Disease 2019, Covid-19 | Phase II | Unknown | Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 | Nov 09, 2020 | ― |
| Best Supportive Care, Masitinib | Indolent Systemic Mastocytosis | Phase III | Unknown | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | Apr 01, 2020 | ― |
| Masitinib | Asthma | Phase III | Completed | Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels | Dec 07, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Masitinib 4.5 Mg/Kg/Day, Riluzole (100 Mg) | Phase III | Amyotrophic Lateral Sclerosis (Als) | Not Yet Recruiting | Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients | Sep 11, 2025 | ― |
| Standard of Care, Masitinib (4.5) | Phase III | Alzheimer Disease | Not Yet Recruiting | Masitinib in Patients With Mild Alzheimer's Disease | Sep 29, 2022 | ― |
| Best Supportive Care, Masitinib 4.5 Mg/Kg/Day, Masitinib 6.0 Mg/Kg/Day | Phase II | Mast Cell Activation Syndrome | Unknown | Masitinib for the Treatment of Severe Mast Cell Activation Syndrome | Jul 02, 2022 | ― |
| Masitinib (4.5) | Phase III | Progressive Multiple Sclerosis | Recruiting | Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis | Jun 28, 2022 | ― |
| Azacitidine, Ab8939 | phase1AndPhase2 | Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, In Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia | Recruiting | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Jan 12, 2022 | ― |
| 14C-Ab1010 | earlyPhase1 | Healthy Volunteers | Completed | Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects | Dec 27, 2021 | ― |
| Masitinib Mesylate | Phase II | COVID19, Sars-Cov2 Infection, Coronavirus Disease 2019 | Unknown | Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 | Sep 16, 2021 | ― |
| Best Supportive Care, Masitinib, Isoquercetin | Phase II | Sars-Cov 2, Coronavirus Disease 2019, Covid-19 | Unknown | Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 | Nov 09, 2020 | ― |
| Best Supportive Care, Masitinib | Phase III | Indolent Systemic Mastocytosis | Unknown | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | Apr 01, 2020 | ― |
| Masitinib | Phase III | Asthma | Completed | Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels | Dec 07, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Ab Science (FR:AB) have in its pipeline
AB Science SA FR:AB is currently developing the following drugs: Masitinib 4.5 Mg/Kg/Day, Riluzole (100 Mg), Standard of Care, Masitinib (4.5), Best Supportive Care, Masitinib 4.5 Mg/Kg/Day, Masitinib 6.0 Mg/Kg/Day, Masitinib (4.5), Azacitidine, Ab8939, 14C-Ab1010, Masitinib Mesylate, Best Supportive Care, Masitinib, Isoquercetin, Best Supportive Care, Masitinib, Masitinib, Gemcitabine, Masitinib, Docetaxel, Prednisone, Masitinib, Riluzole, Masitinib (4.5), Masitinib (6.0), Folfiri, Masitinib (Ab1010), Riluzole, Masitinib (4.5), Masitinib (3.0), Standard of Care, Masitinib, Sunitinib, Masitinib, Dexamethasone, Bortezomib, Masitinib, Methotrexate, Masitinib 3 Mg, Masitinib 6.0 Mg, Dacarbazine, Masitinib, Oral Masitinib, Masitinib (Ab1010), Ab1010, Imatinib, Masitinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.